Russian President Boris Yeltsin has refused to approve therecently-drafted, long-awaited pharmaceutical law which would provide a framework for a reorganized drug sector.
It is understood from media sources in Moscow that Pres Yeltsin objected to the idea of establishing a federal drug control body with regulatory powers, claiming that this would infringe the constitutional rights of the prime minister. He also disagreed with the section of the law dealing with customs duties on drug imports.
It is now expected that the state parliament (duma) will have to find ways of getting round the veto or amend the bill.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze